← Leaderboards
Ross C Donehower
Johns Hopkins University
$2,642,338
Attributed
$2,642,338
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $393.8K · FY2006–07$500K$375K$250K$125K$0
'06
'07
Funding mix
By agency
NIH$2,642,338 · 5
By mechanism
K12$2,429,862 · 1
U01$212,476 · 1
M01$0 · 3
Top collaborators
No co-investigators on record.
Most similar at Johns Hopkins University
Same institution · by research overlap
- Marcia R Cruz Correa$7,817,319
- Richard D Schulick$14,841,770
- Nancy E Davidson$32,860,580
- William George Nelson$34,555,726
- Linda J Van Eldik$37,023,709
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchNeoplasm /Cancer ChemotherapyDrug Screening /EvaluationHuman SubjectAntineoplasticsOncologyCancer PreventionHuman Therapy EvaluationPharmacokineticsClinical Trial Phase ITrainingDosagePediatric Neoplasm /CancerNeoplasm /Cancer SurgeryNeoplasm /Cancer TherapyPostgraduate EducationUniversityFemale Reproductive System NeoplasmEducation Evaluation /PlanningMinority Health ProfessionalRadiation Related Neoplasm /CancerQuinoline AnalogNeoplasm /Cancer DiagnosisNeoplasm /Cancer Pharmacology
Grant awards (18)
Clinical Oncology Research Career Development Program$393,819
K12 · FY2007 · CA · contact PI
Clinical Oncology Research Career Development Program$386,084
K12 · FY2006 · CA · contact PI
Clinical Oncology Research Career Development Program$332,525
K12 · FY2004 · CA
Clinical Oncology Research Career Development Program$412,539
K12 · FY2003 · CA
TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS$0
M01 · FY2002 · RR
PHASE I TRIAL/PHARMACOKINETIS OF TAS 103 SOLID IN TUMORS$0
M01 · FY2002 · RR
PHASE I DOSE ESCALATION, SAFETY, TOLERABILITY OF TAS 103$0
M01 · FY2002 · RR
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$384,214
K12 · FY2001 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$73,125
K12 · FY2001 · CA
TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS$0
M01 · FY2001 · RR
PHASE I DOSE ESCALATION, SAFETY, TOLERABILITY OF TAS 103$0
M01 · FY2001 · RR
PHASE I TRIAL/PHARMACOKINETIS OF TAS 103 SOLID IN TUMORS$0
M01 · FY2001 · RR
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$375,974
K12 · FY2000 · CA
PHASE I TRIALS OF ANTICANCER AGENTS$212,476
U01 · FY2000 · CA
CLINICAL ONCOLOGY RESEARCH CAREER DEVELOPMENT PROGRAM$71,582
K12 · FY2000 · CA
PHASE I TRIAL/PHARMACOKINETIS OF TAS 103 SOLID IN TUMORS$0
M01 · FY2000 · RR
TRIAL OF BRYOSTATIN 1 GIVEN AS CONTINUOUS INFUSION IN CANCER PATIENTS$0
M01 · FY2000 · RR
PHASE I DOSE ESCALATION, SAFETY, TOLERABILITY OF TAS 103$0
M01 · FY2000 · RR